Literature DB >> 8239579

In vitro activity of azithromycin (CP-62,993) against Chlamydia trachomatis and Chlamydia pneumoniae.

A Agacfidan1, J Moncada, J Schachter.   

Abstract

The in vitro susceptibilities of 49 strains of Chlamydia trachomatis and 3 strains of Chlamydia pneumoniae to azithromycin and tetracycline or doxycycline were determined. The MIC of azithromycin ranged from < or = 0.06 to 1.0 micrograms/ml, the MIC of tetracycline ranged from 0.03 to 0.12 micrograms/ml, and the MIC of doxycycline ranged from 0.015 to 0.06 micrograms/ml against C. trachomatis. The MIC ranges for C. pneumoniae were 0.12 to 0.25 micrograms/ml for azithromycin and 0.06 to 0.12 micrograms/ml for tetracycline. All minimal chlamydicidal concentrations were either equal to the MIC or one or two dilutions higher. No strains resistant to these antibiotics were detected. In vitro activity shows that azithromycin is highly active against C. trachomatis and C. pneumoniae.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8239579      PMCID: PMC188064          DOI: 10.1128/AAC.37.9.1746

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

Review 1.  Chlamydia pneumoniae, strain TWAR.

Authors:  J T Grayston
Journal:  Chest       Date:  1989-03       Impact factor: 9.410

2.  Are chlamydial infections the most prevalent venereal disease?

Authors:  J Schachter; L Hanna; E C Hill; S Massad; C W Sheppard; J E Conte; S N Cohen; K F Meyer
Journal:  JAMA       Date:  1975-03-24       Impact factor: 56.272

3.  In vitro evaluation of CP-62,993, erythromycin, clindamycin, and tetracycline against Chlamydia trachomatis.

Authors:  M Walsh; E W Kappus; T C Quinn
Journal:  Antimicrob Agents Chemother       Date:  1987-05       Impact factor: 5.191

4.  Comparison of three-day and five-day courses of azithromycin in the treatment of atypical pneumonia.

Authors:  S Schönwald; V Skerk; I Petricevic; V Car; L Majerus-Misic; M Gunjaca
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-10       Impact factor: 3.267

5.  The pharmacokinetics of azithromycin in human serum and tissues.

Authors:  G Foulds; R M Shepard; R B Johnson
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

6.  Treatment of Chlamydia trachomatis infections: comparison of 1- and 2-g doses of erythromycin daily for seven days.

Authors:  C C Linnemann; C L Heaton; M Ritchey
Journal:  Sex Transm Dis       Date:  1987 Apr-Jun       Impact factor: 2.830

7.  Relative resistance to erythromycin in Chlamydia trachomatis.

Authors:  A Mourad; R L Sweet; N Sugg; J Schachter
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

Review 8.  Treatment of sexually transmitted chlamydial infections.

Authors:  L L Sanders; H R Harrison; A E Washington
Journal:  JAMA       Date:  1986-04-04       Impact factor: 56.272

9.  A controlled trial of a single dose of azithromycin for the treatment of chlamydial urethritis and cervicitis. The Azithromycin for Chlamydial Infections Study Group.

Authors:  D H Martin; T F Mroczkowski; Z A Dalu; J McCarty; R B Jones; S J Hopkins; R B Johnson
Journal:  N Engl J Med       Date:  1992-09-24       Impact factor: 91.245

10.  Chlamydia trachomatis: in vitro susceptibility of genital and ocular isolates to some quinolones, amoxicillin and azithromycin.

Authors:  T Børsum; L Dannevig; G Størvold; K Melby
Journal:  Chemotherapy       Date:  1990       Impact factor: 2.544

View more
  13 in total

1.  Antibiotic susceptibilities of Parachlamydia acanthamoeba in amoebae.

Authors:  M Maurin; A Bryskier; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

2.  In vitro susceptibilities of Chlamydia pneumoniae isolates from German patients and synergistic activity of antibiotic combinations.

Authors:  H M Freidank; P Losch; H Vögele; M Wiedmann-Al-Ahmad
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

Review 3.  Antimicrobial susceptibility and therapy of infections caused by Chlamydia pneumoniae.

Authors:  M R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

4.  In vitro and in vivo activities of azithromycin, a new azalide antibiotic, against chlamydia.

Authors:  Y Niki; M Kimura; N Miyashita; R Soejima
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

5.  In vitro susceptibility of urogenital Chlamydia trachomatis strains in a country with high azithromycin consumption rate.

Authors:  Suncanica Ljubin-Sternak; Tomislav Mestrovic; Tatjana Vilibic-Cavlek; Gordana Mlinaric-Galinovic; Mario Sviben; Alemka Markotic; Visnja Skerk
Journal:  Folia Microbiol (Praha)       Date:  2012-12-29       Impact factor: 2.099

6.  Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia. The Azithromycin Intravenous Clinical Trials Group.

Authors:  J Plouffe; D B Schwartz; A Kolokathis; B W Sherman; P M Arnow; J A Gezon; B Suh; A Anzuetto; R N Greenberg; M Niederman; J A Paladino; J A Ramirez; J Inverso; C A Knirsch
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

Review 7.  Azithromycin. A review of its use in paediatric infectious diseases.

Authors:  H D Langtry; J A Balfour
Journal:  Drugs       Date:  1998-08       Impact factor: 9.546

8.  Effects of azithromycin and rifampin on Chlamydia trachomatis infection in vitro.

Authors:  U Dreses-Werringloer; I Padubrin; H Zeidler; L Köhler
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

Review 9.  International guidelines for the treatment of community-acquired pneumonia in adults: the role of macrolides.

Authors:  Thomas M File; James S Tan
Journal:  Drugs       Date:  2003       Impact factor: 9.546

10.  Lack of macrolide resistance in Chlamydia trachomatis after mass azithromycin distributions for trachoma.

Authors:  Kevin Cyrus Hong; Julius Schachter; Jeanne Moncada; Zhaoxia Zhou; Jenafir House; Thomas M Lietman
Journal:  Emerg Infect Dis       Date:  2009-07       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.